EMERYVILLE, Calif.--(BUSINESS WIRE)-- Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, announced today that Randy Schekman, Ph.D., has been appointed to its Scientific Advisory Board. Dr. Schekman shared the 2013 Nobel Prize for Physiology or Medicine for his ground-breaking work on cell membrane vesicle trafficking. He is currently a Professor in the Department of Molecular and Cell Biology, University of California, Berkeley, and an Investigator of the Howard Hughes Medical Institute.

“Dr. Schekman is a true visionary in the field of medicine, and his scientific research has enabled the production of one third of the world’s supply of insulin and the entire world’s supply of hepatitis B vaccines,” said Dr. Cheng Liu, President and CEO of Eureka Therapeutics. “I have known Randy for more than 20 years, and his scientific leadership and expertise will be invaluable as we advance our anti-AFP ARTEMIS^® ET140203 clinical trial in adult patients with hepatocellular carcinoma (HCC), the predominant type of liver cancer.”

“The approaches Eureka has taken for ‘undruggable’ diseases using TCR mimic antibodies and its proprietary ARTEMIS^® T cell platform are entirely novel and quite powerful,” said Dr. Schekman. “I look forward to working with the Eureka team and its other distinguished SAB members, on advancing its pipeline of therapies to address unmet medical needs in oncology.”

In addition to being awarded the Nobel Prize, Dr. Schekman is the recipient of numerous prizes, including the Lewis S. Rosenstiel Award in basic biomedical science, the Gairdner International Award, the Amgen Award of the Protein Society, the Albert Lasker Award in Basic Medical Research, the Louisa Gross Horwitz Prize of Columbia University, the Dickson Prize in Medicine from the University of Pittsburgh, the Massry Prize, the E.B Wilson Award of the American Society of Cell Biology, the Kornberg-Berg lifetime achievement award from Stanford Medical School and the Otto Warburg Prize of the German Society for Biochemistry and Molecular Biology. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the American Philosophical Society, a Foreign Associate of the Accademia Nazionale dei Lincei and a Foreign Associate of the Royal Society of London.

With the appointment of Dr. Schekman, Eureka’s Scientific Advisory Board consists of five members, including Dr. Stephan Grupp, Section Chief of the Cellular Therapy and Transplant Section at Children’s Hospital of Philadelphia; Dr. Cameron Turtle, Professor and Anderson Family Endowed Chair for Immunotherapy at Fred Hutchinson Cancer Research Center; Dr. David Scheinberg, Director, Experimental Therapeutics Center at Memorial Sloan Kettering Cancer Center; and Dr. Yuman Fong, Chair and Professor of the Department of Surgery Surgical Oncology at City of Hope.

ABOUT EUREKA THERAPEUTICS, INC.

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS^® cell receptor platform and E-ALPHA^® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. ET140203, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005353/en/